Literature DB >> 19202563

Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.

Jasminder Sahi1, Stacy S Shord, Celeste Lindley, Stephen Ferguson, Edward L LeCluyse.   

Abstract

Cytochrome P450 2C9 (CYP2C9) expression is regulated by multiple nuclear receptors including the constitutive androstane receptor (CAR) and pregnane X receptor (PXR). We compared coregulation of CYP2C9 with CYP2B6 and CYP3A4, prototypical target genes for human CAR and PXR using human hepatocyte cultures treated for three days with the PXR activators clotrimazole, rifampin, and ritonavir; the CAR/PXR activator phenobarbital (PB); and the CAR-selective agonists CITCO, (6-(4-chlorophenyl)imidazo[2,1-beta][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) and phenytoin. Clotrimazole, rifampin, ritonavir, phenytoin, and phenobarbital induced CYP2C9 consistent with previous findings for CYP3A4. We observed EC(50) values of 519 microM (phenobarbital), 11 microM (phenytoin), and 0.75 microM (rifampin), similar to those for CYP3A4 induction. Avasimibe, a potent PXR activator, produced nearly identical concentration-dependent CYP2C9 and CYP3A4 activity profiles and EC(50) values. In 17 donors, rifampin increased mean basal CYP2C9 activity from 59 +/- 43 to 143 +/- 68 pmol/mg protein/min; fold induction ranged from 1.4- to 6.4-fold. Enzyme activity and mRNA measurements after rifampin, CITCO and PB treatment demonstrated potency and efficacy consistent with CYP2C9 regulation being analogous to CYP3A4 rather than CYP2B6. We demonstrate that hepatic CYP2C9 is differentially regulated by agonists of CAR and PXR, and despite sharing common regulatory mechanisms with CYP3A4 and CYP2B6; this enzyme exhibits an induction profile more closely aligned with that of CYP3A4. (c) 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19202563     DOI: 10.1002/jbt.20264

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  14 in total

1.  Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.

Authors:  Brian J Kirby; Ann C Collier; Evan D Kharasch; Vaishali Dixit; Pankaj Desai; Dale Whittington; Kenneth E Thummel; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

2.  A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.

Authors:  Pierre-Eric Juif; Margaux Boehler; Yves Donazzolo; Shirin Bruderer; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2017-06-21       Impact factor: 2.953

3.  Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9.

Authors:  Anders Helldén; Ulf Bergman; Karin Engström Hellgren; Michèle Masquelier; Ingela Nilsson Remahl; Ingegerd Odar-Cederlöf; Margareta Ramsjö; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2010-04-20       Impact factor: 2.953

4.  Influence of seeding density and extracellular matrix on bile Acid transport and mrp4 expression in sandwich-cultured mouse hepatocytes.

Authors:  Brandon Swift; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

5.  Assessment of inter-individual variability in predicted phenytoin clearance.

Authors:  Thomas M Polasek; Sebastian Polak; Matthew P Doogue; Amin Rostami-Hodjegan; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

6.  CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.

Authors:  Amarjit S Chaudhry; Thomas J Urban; Jatinder K Lamba; Angela K Birnbaum; Rory P Remmel; Murali Subramanian; Stephen Strom; Joyce H You; Dalia Kasperaviciute; Claudia B Catarino; Rodney A Radtke; Sanjay M Sisodiya; David B Goldstein; Erin G Schuetz
Journal:  J Pharmacol Exp Ther       Date:  2009-10-23       Impact factor: 4.030

Review 7.  PharmVar GeneFocus: CYP2C9.

Authors:  Katrin Sangkuhl; Karla Claudio-Campos; Larisa H Cavallari; Jose A G Agundez; Michelle Whirl-Carrillo; Jorge Duconge; Andria L Del Tredici; Mia Wadelius; Mariana Rodrigues Botton; Erica L Woodahl; Stuart A Scott; Teri E Klein; Victoria M Pratt; Ann K Daly; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2021-07-12       Impact factor: 6.903

Review 8.  Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Authors:  Ann K Daly; Allan E Rettie; Douglas M Fowler; John O Miners
Journal:  J Pers Med       Date:  2017-12-28

9.  Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics.

Authors:  Sabine U Vorrink; Shahid Ullah; Staffan Schmidt; Jatin Nandania; Vidya Velagapudi; Olof Beck; Magnus Ingelman-Sundberg; Volker M Lauschke
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

10.  CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.

Authors:  Lingxin Zhang; Vivekananda Sarangi; Irene Moon; Jia Yu; Duan Liu; Sandhya Devarajan; Joel M Reid; Krishna R Kalari; Liewei Wang; Richard Weinshilboum
Journal:  Clin Transl Sci       Date:  2020-03-10       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.